nodes	percent_of_prediction	percent_of_DWPC	metapath
Trimetrexate—DHFR—Nucleotide Metabolism—NME2—ovarian cancer	0.0497	0.15	CbGpPWpGaD
Trimetrexate—Phosphatase alkaline increased—Altretamine—ovarian cancer	0.0254	0.0547	CcSEcCtD
Trimetrexate—DHFR—Folate Metabolism—FOLR1—ovarian cancer	0.0225	0.0679	CbGpPWpGaD
Trimetrexate—DHFR—myometrium—ovarian cancer	0.0215	0.118	CbGeAlD
Trimetrexate—Blood alkaline phosphatase increased—Altretamine—ovarian cancer	0.0212	0.0457	CcSEcCtD
Trimetrexate—DHFR—embryo—ovarian cancer	0.0207	0.113	CbGeAlD
Trimetrexate—DHFR—uterine cervix—ovarian cancer	0.0168	0.0917	CbGeAlD
Trimetrexate—Trimethoprim—TYMS—ovarian cancer	0.0166	0.798	CrCbGaD
Trimetrexate—Electrolyte imbalance—Vinorelbine—ovarian cancer	0.0165	0.0355	CcSEcCtD
Trimetrexate—DHFR—decidua—ovarian cancer	0.016	0.0873	CbGeAlD
Trimetrexate—DHFR—endometrium—ovarian cancer	0.0152	0.0829	CbGeAlD
Trimetrexate—DHFR—gonad—ovarian cancer	0.0141	0.0769	CbGeAlD
Trimetrexate—DHFR—uterus—ovarian cancer	0.014	0.0764	CbGeAlD
Trimetrexate—DHFR—female reproductive system—ovarian cancer	0.0126	0.0687	CbGeAlD
Trimetrexate—DHFR—G1/S-Specific Transcription—CCNE1—ovarian cancer	0.0125	0.0379	CbGpPWpGaD
Trimetrexate—DHFR—G1/S-Specific Transcription—TYMS—ovarian cancer	0.0123	0.0372	CbGpPWpGaD
Trimetrexate—DHFR—bone marrow—ovarian cancer	0.0119	0.0648	CbGeAlD
Trimetrexate—Hepatotoxicity—Chlorambucil—ovarian cancer	0.0117	0.0252	CcSEcCtD
Trimetrexate—DHFR—female gonad—ovarian cancer	0.0114	0.0625	CbGeAlD
Trimetrexate—DHFR—vagina—ovarian cancer	0.0114	0.0621	CbGeAlD
Trimetrexate—Electrolyte imbalance—Paclitaxel—ovarian cancer	0.0111	0.0238	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—BARD1—ovarian cancer	0.0104	0.0313	CbGpPWpGaD
Trimetrexate—Anaemia—Altretamine—ovarian cancer	0.0103	0.0221	CcSEcCtD
Trimetrexate—DHFR—testis—ovarian cancer	0.0101	0.0554	CbGeAlD
Trimetrexate—Convulsion—Altretamine—ovarian cancer	0.00963	0.0207	CcSEcCtD
Trimetrexate—DHFR—Metabolism of nitric oxide—CAV1—ovarian cancer	0.00909	0.0274	CbGpPWpGaD
Trimetrexate—Thrombocytopenia—Altretamine—ovarian cancer	0.00888	0.0191	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—RBL2—ovarian cancer	0.00876	0.0264	CbGpPWpGaD
Trimetrexate—Blood bilirubin increased—Topotecan—ovarian cancer	0.00851	0.0183	CcSEcCtD
Trimetrexate—DHFR—One Carbon Metabolism—TYMS—ovarian cancer	0.00827	0.0249	CbGpPWpGaD
Trimetrexate—DHFR—E2F mediated regulation of DNA replication—PPP2R1A—ovarian cancer	0.00795	0.024	CbGpPWpGaD
Trimetrexate—Fatigue—Altretamine—ovarian cancer	0.00782	0.0168	CcSEcCtD
Trimetrexate—DHFR—Trans-sulfuration and one carbon metabolism—TYMS—ovarian cancer	0.00743	0.0224	CbGpPWpGaD
Trimetrexate—DHFR—E2F mediated regulation of DNA replication—CCNE1—ovarian cancer	0.00738	0.0223	CbGpPWpGaD
Trimetrexate—DHFR—lymph node—ovarian cancer	0.00735	0.0402	CbGeAlD
Trimetrexate—Blood bilirubin increased—Vinorelbine—ovarian cancer	0.00728	0.0157	CcSEcCtD
Trimetrexate—DHFR—E2F mediated regulation of DNA replication—TYMS—ovarian cancer	0.00725	0.0219	CbGpPWpGaD
Trimetrexate—DHFR—Fluoropyrimidine Activity—TYMS—ovarian cancer	0.00725	0.0219	CbGpPWpGaD
Trimetrexate—Asthenia—Altretamine—ovarian cancer	0.00651	0.014	CcSEcCtD
Trimetrexate—Vomiting—Altretamine—ovarian cancer	0.00577	0.0124	CcSEcCtD
Trimetrexate—Hyponatraemia—Melphalan—ovarian cancer	0.00574	0.0124	CcSEcCtD
Trimetrexate—Nausea—Altretamine—ovarian cancer	0.00539	0.0116	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—RBL2—ovarian cancer	0.00535	0.0162	CbGpPWpGaD
Trimetrexate—Neutropenia—Chlorambucil—ovarian cancer	0.0053	0.0114	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Topotecan—ovarian cancer	0.00526	0.0113	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Topotecan—ovarian cancer	0.00515	0.0111	CcSEcCtD
Trimetrexate—Hepatotoxicity—Docetaxel—ovarian cancer	0.00508	0.0109	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—SKP2—ovarian cancer	0.00506	0.0153	CbGpPWpGaD
Trimetrexate—Hypocalcaemia—Paclitaxel—ovarian cancer	0.00506	0.0109	CcSEcCtD
Trimetrexate—Hyponatraemia—Vinorelbine—ovarian cancer	0.00502	0.0108	CcSEcCtD
Trimetrexate—Body temperature increased—Carboplatin—ovarian cancer	0.00496	0.0107	CcSEcCtD
Trimetrexate—Blood bilirubin increased—Paclitaxel—ovarian cancer	0.00489	0.0105	CcSEcCtD
Trimetrexate—Neutropenia—Topotecan—ovarian cancer	0.00472	0.0102	CcSEcCtD
Trimetrexate—Blood creatinine increased—Vinorelbine—ovarian cancer	0.00468	0.0101	CcSEcCtD
Trimetrexate—Phosphatase alkaline increased—Paclitaxel—ovarian cancer	0.00463	0.00996	CcSEcCtD
Trimetrexate—Neutropenia—Melphalan—ovarian cancer	0.00462	0.00995	CcSEcCtD
Trimetrexate—DHFR—Folate Metabolism—SOD1—ovarian cancer	0.00459	0.0138	CbGpPWpGaD
Trimetrexate—DHFR—Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation—AKT1—ovarian cancer	0.00456	0.0138	CbGpPWpGaD
Trimetrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—FASN—ovarian cancer	0.00453	0.0137	CbGpPWpGaD
Trimetrexate—Aspartate aminotransferase increased—Vinorelbine—ovarian cancer	0.0045	0.00968	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—BRCA1—ovarian cancer	0.00447	0.0135	CbGpPWpGaD
Trimetrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—ovarian cancer	0.00431	0.013	CbGpPWpGaD
Trimetrexate—Serum creatinine increased—Epirubicin—ovarian cancer	0.0043	0.00926	CcSEcCtD
Trimetrexate—DHFR—G1/S Transition—SKP2—ovarian cancer	0.00423	0.0128	CbGpPWpGaD
Trimetrexate—Trimethoprim—ABCB1—ovarian cancer	0.00422	0.202	CrCbGaD
Trimetrexate—DHFR—Cell Cycle—RSF1—ovarian cancer	0.00417	0.0126	CbGpPWpGaD
Trimetrexate—Blood bilirubin increased—Docetaxel—ovarian cancer	0.00415	0.00893	CcSEcCtD
Trimetrexate—DHFR—Folate Metabolism—SOD2—ovarian cancer	0.00413	0.0125	CbGpPWpGaD
Trimetrexate—Neutropenia—Vinorelbine—ovarian cancer	0.00404	0.00869	CcSEcCtD
Trimetrexate—Serum creatinine increased—Doxorubicin—ovarian cancer	0.00398	0.00857	CcSEcCtD
Trimetrexate—Phosphatase alkaline increased—Docetaxel—ovarian cancer	0.00392	0.00844	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—CCNE1—ovarian cancer	0.00391	0.0118	CbGpPWpGaD
Trimetrexate—Blood alkaline phosphatase increased—Paclitaxel—ovarian cancer	0.00386	0.00831	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—TYMS—ovarian cancer	0.00384	0.0116	CbGpPWpGaD
Trimetrexate—Anaemia—Chlorambucil—ovarian cancer	0.00365	0.00786	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—SKP2—ovarian cancer	0.00356	0.0107	CbGpPWpGaD
Trimetrexate—Convulsion—Chlorambucil—ovarian cancer	0.00342	0.00737	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—CCNE1—ovarian cancer	0.0034	0.0103	CbGpPWpGaD
Trimetrexate—Hyponatraemia—Paclitaxel—ovarian cancer	0.00337	0.00726	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—TYMS—ovarian cancer	0.00334	0.0101	CbGpPWpGaD
Trimetrexate—Blood alkaline phosphatase increased—Docetaxel—ovarian cancer	0.00327	0.00705	CcSEcCtD
Trimetrexate—Confusional state—Chlorambucil—ovarian cancer	0.00325	0.007	CcSEcCtD
Trimetrexate—Anaemia—Topotecan—ovarian cancer	0.00325	0.007	CcSEcCtD
Trimetrexate—Anaemia—Melphalan—ovarian cancer	0.00318	0.00685	CcSEcCtD
Trimetrexate—DHFR—Metabolism of nitric oxide—AKT1—ovarian cancer	0.00316	0.00953	CbGpPWpGaD
Trimetrexate—Thrombocytopenia—Chlorambucil—ovarian cancer	0.00316	0.00679	CcSEcCtD
Trimetrexate—Blood creatinine increased—Paclitaxel—ovarian cancer	0.00315	0.00677	CcSEcCtD
Trimetrexate—DHFR—G1/S Transition—PPP2R1A—ovarian cancer	0.00306	0.00922	CbGpPWpGaD
Trimetrexate—Aspartate aminotransferase increased—Paclitaxel—ovarian cancer	0.00303	0.00651	CcSEcCtD
Trimetrexate—Convulsion—Melphalan—ovarian cancer	0.00298	0.00642	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Paclitaxel—ovarian cancer	0.00296	0.00638	CcSEcCtD
Trimetrexate—Hypocalcaemia—Epirubicin—ovarian cancer	0.00289	0.00622	CcSEcCtD
Trimetrexate—Hyponatraemia—Docetaxel—ovarian cancer	0.00286	0.00615	CcSEcCtD
Trimetrexate—DHFR—G1/S Transition—CCNE1—ovarian cancer	0.00284	0.00856	CbGpPWpGaD
Trimetrexate—Thrombocytopenia—Topotecan—ovarian cancer	0.00281	0.00605	CcSEcCtD
Trimetrexate—Blood bilirubin increased—Epirubicin—ovarian cancer	0.0028	0.00602	CcSEcCtD
Trimetrexate—DHFR—G1/S Transition—TYMS—ovarian cancer	0.00279	0.00841	CbGpPWpGaD
Trimetrexate—Anaemia—Vinorelbine—ovarian cancer	0.00278	0.00598	CcSEcCtD
Trimetrexate—Fatigue—Chlorambucil—ovarian cancer	0.00278	0.00598	CcSEcCtD
Trimetrexate—Thrombocytopenia—Melphalan—ovarian cancer	0.00275	0.00592	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CCND2—ovarian cancer	0.00273	0.00824	CbGpPWpGaD
Trimetrexate—Neutropenia—Paclitaxel—ovarian cancer	0.00272	0.00584	CcSEcCtD
Trimetrexate—Hypocalcaemia—Doxorubicin—ovarian cancer	0.00268	0.00576	CcSEcCtD
Trimetrexate—Feeling abnormal—Chlorambucil—ovarian cancer	0.00266	0.00572	CcSEcCtD
Trimetrexate—Phosphatase alkaline increased—Epirubicin—ovarian cancer	0.00265	0.0057	CcSEcCtD
Trimetrexate—Blood bilirubin increased—Doxorubicin—ovarian cancer	0.00259	0.00557	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—PPP2R1A—ovarian cancer	0.00258	0.00777	CbGpPWpGaD
Trimetrexate—Aspartate aminotransferase increased—Docetaxel—ovarian cancer	0.00257	0.00552	CcSEcCtD
Trimetrexate—Body temperature increased—Chlorambucil—ovarian cancer	0.00255	0.00549	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Docetaxel—ovarian cancer	0.00251	0.00541	CcSEcCtD
Trimetrexate—Fatigue—Topotecan—ovarian cancer	0.00248	0.00533	CcSEcCtD
Trimetrexate—Phosphatase alkaline increased—Doxorubicin—ovarian cancer	0.00245	0.00527	CcSEcCtD
Trimetrexate—Fatigue—Melphalan—ovarian cancer	0.00242	0.00521	CcSEcCtD
Trimetrexate—Thrombocytopenia—Vinorelbine—ovarian cancer	0.0024	0.00517	CcSEcCtD
Trimetrexate—DHFR—Fluoropyrimidine Activity—TP53—ovarian cancer	0.0024	0.00725	CbGpPWpGaD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CCNE1—ovarian cancer	0.00239	0.00721	CbGpPWpGaD
Trimetrexate—Feeling abnormal—Topotecan—ovarian cancer	0.00237	0.00509	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—TYMS—ovarian cancer	0.00235	0.00709	CbGpPWpGaD
Trimetrexate—Asthenia—Chlorambucil—ovarian cancer	0.00231	0.00498	CcSEcCtD
Trimetrexate—Neutropenia—Docetaxel—ovarian cancer	0.0023	0.00495	CcSEcCtD
Trimetrexate—Pruritus—Chlorambucil—ovarian cancer	0.00228	0.00491	CcSEcCtD
Trimetrexate—Body temperature increased—Topotecan—ovarian cancer	0.00227	0.00488	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Epirubicin—ovarian cancer	0.00221	0.00475	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—RAD51C—ovarian cancer	0.00219	0.0066	CbGpPWpGaD
Trimetrexate—DHFR—Folate Metabolism—IL2—ovarian cancer	0.00215	0.00649	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—PPP1CC—ovarian cancer	0.00214	0.00645	CbGpPWpGaD
Trimetrexate—Fatigue—Vinorelbine—ovarian cancer	0.00212	0.00456	CcSEcCtD
Trimetrexate—Asthenia—Topotecan—ovarian cancer	0.00206	0.00443	CcSEcCtD
Trimetrexate—Vomiting—Chlorambucil—ovarian cancer	0.00205	0.00441	CcSEcCtD
Trimetrexate—Blood alkaline phosphatase increased—Doxorubicin—ovarian cancer	0.00204	0.0044	CcSEcCtD
Trimetrexate—Pruritus—Topotecan—ovarian cancer	0.00203	0.00437	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—CDKN1B—ovarian cancer	0.00203	0.00612	CbGpPWpGaD
Trimetrexate—Feeling abnormal—Vinorelbine—ovarian cancer	0.00202	0.00435	CcSEcCtD
Trimetrexate—Asthenia—Melphalan—ovarian cancer	0.00202	0.00434	CcSEcCtD
Trimetrexate—Pruritus—Melphalan—ovarian cancer	0.00199	0.00428	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle, Mitotic—RBL2—ovarian cancer	0.00196	0.00592	CbGpPWpGaD
Trimetrexate—Body temperature increased—Vinorelbine—ovarian cancer	0.00194	0.00418	CcSEcCtD
Trimetrexate—Hyponatraemia—Epirubicin—ovarian cancer	0.00193	0.00415	CcSEcCtD
Trimetrexate—Nausea—Chlorambucil—ovarian cancer	0.00192	0.00412	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—PPP1CC—ovarian cancer	0.00191	0.00577	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HSD17B6—ovarian cancer	0.0019	0.00575	CbGpPWpGaD
Trimetrexate—Anaemia—Paclitaxel—ovarian cancer	0.00187	0.00403	CcSEcCtD
Trimetrexate—Vomiting—Topotecan—ovarian cancer	0.00183	0.00393	CcSEcCtD
Trimetrexate—Rash—Topotecan—ovarian cancer	0.00181	0.00389	CcSEcCtD
Trimetrexate—Dermatitis—Topotecan—ovarian cancer	0.00181	0.00389	CcSEcCtD
Trimetrexate—Blood creatinine increased—Epirubicin—ovarian cancer	0.0018	0.00387	CcSEcCtD
Trimetrexate—Vomiting—Melphalan—ovarian cancer	0.00179	0.00385	CcSEcCtD
Trimetrexate—Hyponatraemia—Doxorubicin—ovarian cancer	0.00178	0.00384	CcSEcCtD
Trimetrexate—Rash—Melphalan—ovarian cancer	0.00177	0.00381	CcSEcCtD
Trimetrexate—Dermatitis—Melphalan—ovarian cancer	0.00177	0.00381	CcSEcCtD
Trimetrexate—Asthenia—Vinorelbine—ovarian cancer	0.00176	0.00379	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—CDKN1B—ovarian cancer	0.00176	0.00531	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—RBL2—ovarian cancer	0.00176	0.0053	CbGpPWpGaD
Trimetrexate—Convulsion—Paclitaxel—ovarian cancer	0.00175	0.00377	CcSEcCtD
Trimetrexate—Pruritus—Vinorelbine—ovarian cancer	0.00174	0.00374	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.00173	0.00372	CcSEcCtD
Trimetrexate—Nausea—Topotecan—ovarian cancer	0.00171	0.00367	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.00169	0.00365	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—CCND1—ovarian cancer	0.00168	0.00507	CbGpPWpGaD
Trimetrexate—Nausea—Melphalan—ovarian cancer	0.00167	0.00359	CcSEcCtD
Trimetrexate—Confusional state—Paclitaxel—ovarian cancer	0.00167	0.00358	CcSEcCtD
Trimetrexate—Blood creatinine increased—Doxorubicin—ovarian cancer	0.00167	0.00358	CcSEcCtD
Trimetrexate—Thrombocytopenia—Paclitaxel—ovarian cancer	0.00162	0.00348	CcSEcCtD
Trimetrexate—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.0016	0.00344	CcSEcCtD
Trimetrexate—Anaemia—Docetaxel—ovarian cancer	0.00159	0.00341	CcSEcCtD
Trimetrexate—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.00157	0.00337	CcSEcCtD
Trimetrexate—Vomiting—Vinorelbine—ovarian cancer	0.00156	0.00336	CcSEcCtD
Trimetrexate—Neutropenia—Epirubicin—ovarian cancer	0.00155	0.00334	CcSEcCtD
Trimetrexate—DHFR—E2F transcription factor network—MYC—ovarian cancer	0.00155	0.00468	CbGpPWpGaD
Trimetrexate—Rash—Vinorelbine—ovarian cancer	0.00155	0.00333	CcSEcCtD
Trimetrexate—Dermatitis—Vinorelbine—ovarian cancer	0.00155	0.00333	CcSEcCtD
Trimetrexate—DHFR—Disease—CHMP4C—ovarian cancer	0.00152	0.00459	CbGpPWpGaD
Trimetrexate—Convulsion—Docetaxel—ovarian cancer	0.00149	0.0032	CcSEcCtD
Trimetrexate—DHFR—G1/S Transition—CDKN1B—ovarian cancer	0.00147	0.00444	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—NME2—ovarian cancer	0.00146	0.0044	CbGpPWpGaD
Trimetrexate—Nausea—Vinorelbine—ovarian cancer	0.00146	0.00314	CcSEcCtD
Trimetrexate—Neutropenia—Doxorubicin—ovarian cancer	0.00144	0.00309	CcSEcCtD
Trimetrexate—Fatigue—Paclitaxel—ovarian cancer	0.00142	0.00306	CcSEcCtD
Trimetrexate—Confusional state—Docetaxel—ovarian cancer	0.00141	0.00304	CcSEcCtD
Trimetrexate—DHFR—Folate Metabolism—TP53—ovarian cancer	0.00138	0.00417	CbGpPWpGaD
Trimetrexate—Thrombocytopenia—Docetaxel—ovarian cancer	0.00137	0.00295	CcSEcCtD
Trimetrexate—Feeling abnormal—Paclitaxel—ovarian cancer	0.00136	0.00293	CcSEcCtD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—MYC—ovarian cancer	0.00135	0.00407	CbGpPWpGaD
Trimetrexate—DHFR—Disease—BCL9—ovarian cancer	0.00132	0.00398	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—SKP2—ovarian cancer	0.00131	0.00394	CbGpPWpGaD
Trimetrexate—Body temperature increased—Paclitaxel—ovarian cancer	0.00131	0.00281	CcSEcCtD
Trimetrexate—DHFR—Folate Metabolism—IL6—ovarian cancer	0.00126	0.00381	CbGpPWpGaD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CDKN1B—ovarian cancer	0.00124	0.00374	CbGpPWpGaD
Trimetrexate—Fatigue—Docetaxel—ovarian cancer	0.00121	0.0026	CcSEcCtD
Trimetrexate—Asthenia—Paclitaxel—ovarian cancer	0.00119	0.00255	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—CCND1—ovarian cancer	0.00118	0.00357	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—MLH1—ovarian cancer	0.00118	0.00356	CbGpPWpGaD
Trimetrexate—Pruritus—Paclitaxel—ovarian cancer	0.00117	0.00251	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—SKP2—ovarian cancer	0.00117	0.00352	CbGpPWpGaD
Trimetrexate—Feeling abnormal—Docetaxel—ovarian cancer	0.00115	0.00248	CcSEcCtD
Trimetrexate—DHFR—G1/S Transition—MYC—ovarian cancer	0.00113	0.0034	CbGpPWpGaD
Trimetrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—ovarian cancer	0.00111	0.00334	CbGpPWpGaD
Trimetrexate—Body temperature increased—Docetaxel—ovarian cancer	0.00111	0.00238	CcSEcCtD
Trimetrexate—Anaemia—Epirubicin—ovarian cancer	0.00107	0.0023	CcSEcCtD
Trimetrexate—Vomiting—Paclitaxel—ovarian cancer	0.00105	0.00226	CcSEcCtD
Trimetrexate—Rash—Paclitaxel—ovarian cancer	0.00104	0.00224	CcSEcCtD
Trimetrexate—Dermatitis—Paclitaxel—ovarian cancer	0.00104	0.00224	CcSEcCtD
Trimetrexate—Asthenia—Docetaxel—ovarian cancer	0.001	0.00216	CcSEcCtD
Trimetrexate—Convulsion—Epirubicin—ovarian cancer	0.001	0.00216	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CCND2—ovarian cancer	0.001	0.00302	CbGpPWpGaD
Trimetrexate—Pruritus—Docetaxel—ovarian cancer	0.000991	0.00213	CcSEcCtD
Trimetrexate—Anaemia—Doxorubicin—ovarian cancer	0.00099	0.00213	CcSEcCtD
Trimetrexate—Nausea—Paclitaxel—ovarian cancer	0.000981	0.00211	CcSEcCtD
Trimetrexate—DHFR—Disease—PPP1CC—ovarian cancer	0.000981	0.00296	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CHEK2—ovarian cancer	0.000956	0.00288	CbGpPWpGaD
Trimetrexate—Confusional state—Epirubicin—ovarian cancer	0.000952	0.00205	CcSEcCtD
Trimetrexate—DHFR—Mitotic G1-G1/S phases—MYC—ovarian cancer	0.000949	0.00286	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—PPP2R1A—ovarian cancer	0.000945	0.00285	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CYTB—ovarian cancer	0.00094	0.00284	CbGpPWpGaD
Trimetrexate—Convulsion—Doxorubicin—ovarian cancer	0.000928	0.002	CcSEcCtD
Trimetrexate—Thrombocytopenia—Epirubicin—ovarian cancer	0.000925	0.00199	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—CCND2—ovarian cancer	0.000895	0.0027	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—BRCA1—ovarian cancer	0.000895	0.0027	CbGpPWpGaD
Trimetrexate—Vomiting—Docetaxel—ovarian cancer	0.00089	0.00192	CcSEcCtD
Trimetrexate—Rash—Docetaxel—ovarian cancer	0.000883	0.0019	CcSEcCtD
Trimetrexate—Dermatitis—Docetaxel—ovarian cancer	0.000882	0.0019	CcSEcCtD
Trimetrexate—Confusional state—Doxorubicin—ovarian cancer	0.000881	0.0019	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CCNE1—ovarian cancer	0.000877	0.00265	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—TYMS—ovarian cancer	0.000861	0.0026	CbGpPWpGaD
Trimetrexate—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000856	0.00184	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—PPP2R1A—ovarian cancer	0.000845	0.00255	CbGpPWpGaD
Trimetrexate—Nausea—Docetaxel—ovarian cancer	0.000832	0.00179	CcSEcCtD
Trimetrexate—DHFR—Metabolism—BRIP1—ovarian cancer	0.000822	0.00248	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PPP1CC—ovarian cancer	0.000822	0.00248	CbGpPWpGaD
Trimetrexate—Fatigue—Epirubicin—ovarian cancer	0.000814	0.00175	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—BRCA2—ovarian cancer	0.00081	0.00244	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CCNE1—ovarian cancer	0.000784	0.00237	CbGpPWpGaD
Trimetrexate—Feeling abnormal—Epirubicin—ovarian cancer	0.000778	0.00167	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle, Mitotic—BIRC5—ovarian cancer	0.000775	0.00234	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—TYMS—ovarian cancer	0.00077	0.00232	CbGpPWpGaD
Trimetrexate—Fatigue—Doxorubicin—ovarian cancer	0.000753	0.00162	CcSEcCtD
Trimetrexate—Body temperature increased—Epirubicin—ovarian cancer	0.000747	0.00161	CcSEcCtD
Trimetrexate—DHFR—Disease—HDAC6—ovarian cancer	0.000744	0.00224	CbGpPWpGaD
Trimetrexate—Feeling abnormal—Doxorubicin—ovarian cancer	0.00072	0.00155	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—BIRC5—ovarian cancer	0.000693	0.00209	CbGpPWpGaD
Trimetrexate—Body temperature increased—Doxorubicin—ovarian cancer	0.000691	0.00149	CcSEcCtD
Trimetrexate—Asthenia—Epirubicin—ovarian cancer	0.000678	0.00146	CcSEcCtD
Trimetrexate—DHFR—Cell Cycle—TERT—ovarian cancer	0.000671	0.00202	CbGpPWpGaD
Trimetrexate—Pruritus—Epirubicin—ovarian cancer	0.000668	0.00144	CcSEcCtD
Trimetrexate—DHFR—Disease—XIAP—ovarian cancer	0.000645	0.00194	CbGpPWpGaD
Trimetrexate—DHFR—Disease—SMARCA4—ovarian cancer	0.000628	0.0019	CbGpPWpGaD
Trimetrexate—Asthenia—Doxorubicin—ovarian cancer	0.000627	0.00135	CcSEcCtD
Trimetrexate—Pruritus—Doxorubicin—ovarian cancer	0.000618	0.00133	CcSEcCtD
Trimetrexate—DHFR—Disease—EREG—ovarian cancer	0.000613	0.00185	CbGpPWpGaD
Trimetrexate—Vomiting—Epirubicin—ovarian cancer	0.0006	0.00129	CcSEcCtD
Trimetrexate—Rash—Epirubicin—ovarian cancer	0.000595	0.00128	CcSEcCtD
Trimetrexate—Dermatitis—Epirubicin—ovarian cancer	0.000595	0.00128	CcSEcCtD
Trimetrexate—Nausea—Epirubicin—ovarian cancer	0.000561	0.00121	CcSEcCtD
Trimetrexate—Vomiting—Doxorubicin—ovarian cancer	0.000556	0.0012	CcSEcCtD
Trimetrexate—DHFR—Metabolism—YAP1—ovarian cancer	0.000551	0.00166	CbGpPWpGaD
Trimetrexate—Rash—Doxorubicin—ovarian cancer	0.000551	0.00119	CcSEcCtD
Trimetrexate—Dermatitis—Doxorubicin—ovarian cancer	0.00055	0.00118	CcSEcCtD
Trimetrexate—DHFR—Disease—FASN—ovarian cancer	0.000536	0.00162	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PARP1—ovarian cancer	0.000534	0.00161	CbGpPWpGaD
Trimetrexate—Nausea—Doxorubicin—ovarian cancer	0.000519	0.00112	CcSEcCtD
Trimetrexate—DHFR—Disease—SLC2A1—ovarian cancer	0.00051	0.00154	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	0.000455	0.00137	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—FASN—ovarian cancer	0.000449	0.00136	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—SLC5A5—ovarian cancer	0.000442	0.00133	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—CCND1—ovarian cancer	0.000434	0.00131	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PPP2R1A—ovarian cancer	0.000433	0.00131	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—SLC2A1—ovarian cancer	0.000427	0.00129	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CYP1B1—ovarian cancer	0.000409	0.00123	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CDKN1B—ovarian cancer	0.000407	0.00123	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—CCND1—ovarian cancer	0.000388	0.00117	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PPP2R1A—ovarian cancer	0.000363	0.00109	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—MAPK3—ovarian cancer	0.000358	0.00108	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—MYC—ovarian cancer	0.000348	0.00105	CbGpPWpGaD
Trimetrexate—DHFR—Disease—TERT—ovarian cancer	0.000344	0.00104	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle, Mitotic—MAPK1—ovarian cancer	0.00034	0.00103	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—ABCB1—ovarian cancer	0.000337	0.00102	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—TYMS—ovarian cancer	0.000331	0.000998	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—MAPK3—ovarian cancer	0.00032	0.000965	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CAV1—ovarian cancer	0.000318	0.00096	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—MYC—ovarian cancer	0.000311	0.000938	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—MAPK1—ovarian cancer	0.000304	0.000918	CbGpPWpGaD
Trimetrexate—DHFR—Disease—IL6ST—ovarian cancer	0.000302	0.000911	CbGpPWpGaD
Trimetrexate—DHFR—Disease—APC—ovarian cancer	0.00029	0.000875	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—CAV1—ovarian cancer	0.000267	0.000804	CbGpPWpGaD
Trimetrexate—DHFR—Cell Cycle—TP53—ovarian cancer	0.000255	0.000771	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PIK3CD—ovarian cancer	0.000255	0.000769	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PIK3CG—ovarian cancer	0.000243	0.000733	CbGpPWpGaD
Trimetrexate—DHFR—Disease—ERBB2—ovarian cancer	0.000225	0.000679	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PIK3CB—ovarian cancer	0.000222	0.00067	CbGpPWpGaD
Trimetrexate—DHFR—Disease—MTOR—ovarian cancer	0.000222	0.00067	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PIK3CD—ovarian cancer	0.000214	0.000644	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CDKN1B—ovarian cancer	0.000209	0.000629	CbGpPWpGaD
Trimetrexate—DHFR—Disease—CTNNB1—ovarian cancer	0.000197	0.000594	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PTEN—ovarian cancer	0.000192	0.000579	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PIK3CB—ovarian cancer	0.000186	0.000561	CbGpPWpGaD
Trimetrexate—DHFR—Disease—STAT3—ovarian cancer	0.000172	0.000518	CbGpPWpGaD
Trimetrexate—DHFR—Disease—NRAS—ovarian cancer	0.000171	0.000517	CbGpPWpGaD
Trimetrexate—DHFR—Disease—MAPK3—ovarian cancer	0.000164	0.000495	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PTEN—ovarian cancer	0.000161	0.000485	CbGpPWpGaD
Trimetrexate—DHFR—Disease—MYC—ovarian cancer	0.00016	0.000481	CbGpPWpGaD
Trimetrexate—DHFR—Disease—MAPK1—ovarian cancer	0.000156	0.000471	CbGpPWpGaD
Trimetrexate—DHFR—Disease—EGFR—ovarian cancer	0.000156	0.000471	CbGpPWpGaD
Trimetrexate—DHFR—Disease—KRAS—ovarian cancer	0.000147	0.000445	CbGpPWpGaD
Trimetrexate—DHFR—Disease—PIK3CA—ovarian cancer	0.000135	0.000409	CbGpPWpGaD
Trimetrexate—DHFR—Disease—HRAS—ovarian cancer	0.000125	0.000378	CbGpPWpGaD
Trimetrexate—DHFR—Disease—IL6—ovarian cancer	0.00012	0.000362	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—PIK3CA—ovarian cancer	0.000113	0.000342	CbGpPWpGaD
Trimetrexate—DHFR—Disease—AKT1—ovarian cancer	0.000111	0.000334	CbGpPWpGaD
Trimetrexate—DHFR—Metabolism—AKT1—ovarian cancer	9.27e-05	0.00028	CbGpPWpGaD
